Protocol Ledger

NCT06611163 · Phase III · ACTIVE NOT RECRUITING

A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.

Interventional Phase III clinical trial protocol NCT06611163 sponsored by Sun Pharmaceutical Industries Limited in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-03-21 Enrollment: 206 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06611163
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)206 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06611163
Protocol FieldVerified Registry Value
NCT IdentifierNCT06611163
Consolidated Lead SponsorSun Pharmaceutical Industries Limited
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment206 participants (ACTUAL)
Registered Start Date2025-03-21
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06611163
Hospital Research SiteLocationSite Profile
California Dermatology & Clinical Research InstituteEncinitas, CAOpen Hospital Dossier ->
Center for Dermatology Clinical Research, Inc.Fremont, CAOpen Hospital Dossier ->
Dermatology Research AssociatesLos Angeles, CAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI